{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:14:44Z","timestamp":1784970884828,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>During the past two decades, an increasing number of patients with very-late-onset myasthenia gravis (v-LOMG) with an onset age of 65 years or older have been identified. However, few studies explore the predictors of secondary generalization in patients with v-LOMG with pure ocular onset. In this retrospective cohort study, 69 patients with v-LOMG were divided into ocular MG (OMG) and generalized MG (GMG), and the clinical characteristics and outcomes were compared. Cox regression analysis was performed to explore the predictors of generalization. The average onset age of the study population was 73.1 \u00b1 4.2 years and the median disease duration was 48.0 months (interquartile range, 32.5\u201364.5 months). Serum acetylcholine receptor (AChR) antibody was detected in up to 86% of patients and concomitant diseases in approximately half of the patients. Male predominance was seen in OMG group while female predominance in GMG group (<jats:italic>p<\/jats:italic> = 0.043). Patients with OMG showed a lower positive rate of repetitive nerve stimulation (RNS) than those with GMG (<jats:italic>p<\/jats:italic> = 0.014), and favorable outcomes were obtained in more patients with OMG than those with GMG (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). Of the 51 patients with pure ocular onset, 25 (49.0%) underwent secondary generalization. A higher probability of generalization was found in patients with positive RNS results and without immunotherapy (<jats:italic>p<\/jats:italic> = 0.018 and &amp;lt;0.001). Upon Cox regression analysis, immunotherapy was negatively associated with secondary generalization [HR (hazard ratio) 0.077, 95%CI [0.024\u20130.247], <jats:italic>p<\/jats:italic> &amp;lt; 0.001]. Altogether, compared to the patients with very-late-onset GMG, the counterparts with OMG exhibit a significantly higher female predominance and a lower positive rate of RNS tests, especially on facial and accessory nerves. Lack of immunotherapy is the only predictor of secondary generalization in those with pure ocular onset.<\/jats:p>","DOI":"10.3389\/fneur.2022.857402","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T08:21:05Z","timestamp":1650874865000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis With Pure Ocular Onset"],"prefix":"10.3389","volume":"13","author":[{"given":"Sijia","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1382","DOI":"10.1212\/WNL.0000000000012604","article-title":"Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG Study","volume":"97","author":"Petersson","year":"2021","journal-title":"Neurology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/01616412.2018.1525121","article-title":"Clinical differences of early and late-onset myasthenia gravis in 985 patients","volume":"41","author":"Fan","year":"2019","journal-title":"Neurol Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s00415-012-6478-6","article-title":"Characteristics of late-onset myasthenia gravis","volume":"259","author":"Zivkovi\u0107","year":"2012","journal-title":"J Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/mus.25526","article-title":"Head-drop: a frequent feature of late-onset myasthenia gravis","volume":"56","author":"Sih","year":"2017","journal-title":"Muscle Nerve."},{"key":"B6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s13760-019-01252-x","article-title":"Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome","volume":"120","author":"Yildiz Celik","year":"2020","journal-title":"Acta Neurol Belg."},{"key":"B7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ensci.2016.02.004","article-title":"Late-onset myasthenia gravis is predisposed to become generalized in the elderly","volume":"2","author":"Sakai","year":"2016","journal-title":"eNeurologicalSci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1212\/WNL.40.5.786","article-title":"The relationship of age to outcome in myasthenia gravis","volume":"40","author":"Donaldson","year":"1990","journal-title":"Neurology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s40266-015-0297-2","article-title":"Treatment of myasthenia gravis in the aged","volume":"32","author":"Alkhawajah","year":"2015","journal-title":"Drugs Aging."},{"key":"B10","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/mus.27369","article-title":"Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis","volume":"64","author":"Vijayan","year":"2021","journal-title":"Muscle Nerve."},{"key":"B11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12883-020-01805-1","article-title":"Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China","volume":"20","author":"Ding","year":"2020","journal-title":"BMC Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00415-018-9056-8","article-title":"Generalization after ocular onset in myasthenia gravis: a case series in Germany","volume":"265","author":"Li","year":"2018","journal-title":"J Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/WNO.0000000000000350","article-title":"Ocular myasthenia gravis: toward a risk of generalization score and sample size calculation for a randomized controlled trial of disease modification","volume":"36","author":"Wong","year":"2016","journal-title":"J Neuroophthalmol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000507853","article-title":"Adult ocular myasthenia gravis conversion: a single-center retrospective analysis in China","volume":"83","author":"Feng","year":"2020","journal-title":"Eur Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1756286419876521","DOI":"10.1177\/1756286419876521","article-title":"Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis","volume":"12","author":"Li","year":"2019","journal-title":"Ther Adv Neurol Disord."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1212\/01.WNL.0000050461.05432.C5","article-title":"Myasthenia gravis: a higher than expected incidence in the elderly","volume":"60","author":"Aragon\u00e8s","year":"2003","journal-title":"Neurology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1212\/01.wnl.0000176067.32186.a3","article-title":"Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis","volume":"65","author":"Somnier","year":"2005","journal-title":"Neurology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00415-010-5651-z","article-title":"Myasthenia gravis: a changing pattern of incidence","volume":"257","author":"Casetta","year":"2010","journal-title":"J Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","article-title":"Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey","volume":"305","author":"Murai","year":"2011","journal-title":"J Neurol Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41582-020-0345-3","article-title":"New insights into very-late-onset myasthenia gravis","volume":"16","author":"Barnett","year":"2020","journal-title":"Nat Rev Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2012.10.028","article-title":"Myasthenia gravis in the elderly","volume":"325","author":"Hellmann","year":"2013","journal-title":"J Neurol Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/j.clinph.2011.02.026","article-title":"Electrophysiological and immunological study in myasthenia gravis: diagnostic sensitivity and correlation","volume":"122","author":"Witoonpanich","year":"2011","journal-title":"Clin Neurophysiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"985","DOI":"10.4103\/0301-4738.145987","article-title":"Ocular myasthenia gravis: a review","volume":"62","author":"Nair","year":"2014","journal-title":"Indian J Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","article-title":"UK Myasthenia Gravis Survey. Evidence of underdiagnosis of myasthenia gravis in older people","volume":"74","author":"Vincent","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","article-title":"Clinical predictors for the prognosis of myasthenia gravis","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.4049\/jimmunol.0901618","article-title":"Maintenance of immune tolerance to a neo-self AChR antigen with aging: implications for late-onset autoimmunity","volume":"184","author":"Stacy","year":"2010","journal-title":"J Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2165\/11316480-000000000-00000","article-title":"Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions","volume":"26","author":"Kuypers","year":"2009","journal-title":"Drugs Aging."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jama.289.9.1107","article-title":"Incidence and preventability of adverse drug events among older persons in the ambulatory setting","volume":"289","author":"Gurwitz","year":"2003","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals","volume":"72","author":"Alshekhlee","year":"2009","journal-title":"Neurology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1600-0404.1996.tb00517.x","article-title":"Myasthenia gravis in the elderly: a hospital based study","volume":"93","author":"Antonini","year":"1996","journal-title":"Acta Neurol Scand."},{"key":"B32","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1749-6632.1998.tb11017.x","article-title":"Late-onset myasthenia gravis. Follow-up of 113 patients diagnosed after age 60","volume":"841","author":"Slesak","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/mus.23964","article-title":"Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing","volume":"48","author":"Alkhawajah","year":"2013","journal-title":"Muscle Nerve."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.857402\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T08:21:06Z","timestamp":1650874866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.857402\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":33,"alternative-id":["10.3389\/fneur.2022.857402"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.857402","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"article-number":"857402"}}